Showing 1771-1780 of 2105 results for "".
- Children Treated With Risdiplam Continue Meeting Motor Milestones After 1 Yearhttps://practicalneurology.com/news/children-treated-with-risdiplam-continue-meeting-motor-milestones-after-1-year/2469652/Results from Part 2 of a pivotal clinical study show that infants with symptomatic Type 1 spinal muscular atrophy (SMA) treated with risdiplam (Evrysdi; PTC Therapeutics, South Plainfield, NJ) showed significant improvements in survival, motor milestones, and motor function compared with the natu
- Viltolarsen Treatment of Muscular Dystrophy Improves Mobility Over More Than 2 Yearshttps://practicalneurology.com/news/viltolarsen-treatment-of-muscular-dystrophy-improves-mobility-over-more-than-a-2-years/2469630/Interim analyses of an open-label extension trial (NCT04337112) have shown mobility improvement in individuals with Duchenne muscular dystrophy (DMD) after 109 weeks of treatment with vi
- Vote for Your Favorite Photo at DravetPhotoDiary.com to Support the Epilepsy Foundation and the Dravet Syndrome Foundationhttps://practicalneurology.com/news/vote-for-your-favorite-photo-at-dravetphotodiarycom-to-support-the-epilepsy-foundation-and-the-dravet-syndrome-foundation/2469626/To celebrate the increased functionality that can come with effective treatments for Dravet syndrome, families and individuals living with the condition have been sharing photos of their family life on DravetPhotoDiary.com. Fo
- Decreased 10-Year Disability Progression in Multiple Sclerosis Seen With Autologous Hematopoietic Stem Cell Treatmenthttps://practicalneurology.com/news/decreased-10-year-disability-progression-in-multiple-sclerosis-seen-with-autologous-hematopoietic-stem-cell-treatment/2469482/A new study published in Neurology suggests autologous hematopoietic stem cell transplant (aHSCT) therapy for multiple sclerosis may have efficacy for preventing disability progression of multiple sclerosi
- Erenumab Reductions in Monthly Migraine Days Sustained for up to 2 Years In Episodic Migrainehttps://practicalneurology.com/news/erenumab-reductions-in-monthly-migraine-days-sustained-for-up-to-2-years-in-episodic-migraine/2469395/In the open-label extension period of a phase 2 study (NCT01952574), treatment with erenumab (Aimovig; Amgen, Thousand Oak, CA) resulted in sustained reductions in monthly migraine days (MMD) and use of acute migraine-specific medications (AMSM). Additionally, the safety profile was consistent wi
- Fenfluramine Consistently Reduces Seizures in Children and Young Adults with Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-consistently-reduces-seizures-in-children-and-young-adults-with-dravet-syndrome/2469374/A third phase 3 study (NCT02926898) further validates the significant reduction of convulsive seizures seen when individuals with Dravet syndrome (DS) receive fenfluramine (Fintepla; Zogenix Inc.,
- Cerebral Venous Thrombosis Incidence Is Increasinghttps://practicalneurology.com/news/cerebral-venous-thrombosis-incidence-is-increasing/2469362/A study published in Neurology, found that cerebral venous thrombosis (CVT) incidence is higher than previously reported and has also increased since 2006. Increased incidence was mainly in men and women more than age 45. Consistent with prior data, the incidence of CVT remained highest in younge
- New DNA-Plasmid Immunotherapy Treatment, in Combination with Cemiplimab, for Glioblastoma Results in 85% 1-Year Survival Ratehttps://practicalneurology.com/news/new-dna-plasmid-immunotherapy-treatment-in-combination-with-cemiplimab-for-glioblastoma-results-in-85-1-year-survival-rate/2469261/In a phase 1/2 clinical trial (NCT03491683), 85% (44 out of 52) of individuals newly diagnosed with glioblastoma multiforme (GBM) who received 2 new immunotherapeutic agents (INO-5401, INO-9012, I
- Children and Teens Caring for Their Parents with ALS Need More Education and Support From Other Youthhttps://practicalneurology.com/news/children-and-teens-caring-for-their-parents-with-als-need-more-education-and-support-from-other-youth/2469193/Children and teens with family members with amyotrophic lateral sclerosis (ALS) help with bathing, dressing, eating, and all types of caregiving activities. However, they may not have training or enough information about the disease. A study (published somewhere? if so state that; if not, s
- Children Treated Presymptomatically With Nusinersen Continue Surviving and Meeting Motor Milestones After 2 Years of Treatmenthttps://practicalneurology.com/news/children-treated-presymptomatically-with-nusinersen-continue-surviving-and-meeting-motor-milestones-after-2-years-of-treatment/2469037/As published in the journal Neuromuscular Disorders, 25 children who were genetically diagnosed with spinal muscular atrophy (SMA) and treated presymptomatically with nusinersen (Spinraza; Biogen, Cambridge,